SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations
13 Agosto 2024 - 6:05AM
Business Wire
SOLVD Health, a patient intelligence company focused on creating
innovative technologies that identify an individual's risk of
disease by discovering and converting biological signals into
predictive, contextual health insights, has appointed Mark
Hazeltine as Chief Financial Officer and Ron McCullough as Senior
Vice President of Clinical Operations.
Mr. Hazeltine has extensive experience in finance, operations,
and strategic development. Before joining SOLVD Health, he served
as Chief Business Officer at Exagen Inc., a diagnostics company
specializing in autoimmune testing. At Exagen, Mr. Hazeltine held
various roles in finance and corporate development, including
Senior Vice President of Finance & Corporate Development,
General Manager and Chief Operating Officer. He co-led the IPO
process and significantly increased reimbursement rates through
improved billing processes. Mr. Hazeltine holds a Bachelor of
Business Administration from the University of San Diego and a
Master of Business Administration from the University of Southern
California.
“Mark's proven track record of driving change, fostering growth,
and providing strategic financial leadership in both startup and
established healthcare organizations makes him the ideal addition
to our executive team,” said SOLVD Health founder and CEO Keri
Donaldson. “His deep understanding of the diagnostics industry,
combined with his successful IPO experience, fundraising, and
operational excellence, will be invaluable as we continue to scale
our business and pursue our mission.”
Dr. McCullough is a seasoned executive with a strong background
in commercializing high-potential research, clinical diagnostics,
and business innovation. He served as the Chief Scientific Officer
and co-founder at Intrigue Health, a medical device and digital
health startup. Dr. McCullough also chaired the Strategic Advisory
Board at Claire Health and served as Senior Vice President of
Operations at Pathnostics. He holds a Doctor of Philosophy in
molecular and cellular biology and biochemistry from Boston
University, a Master of Business Administration from the University
of San Diego, and a Bachelor of Science in chemistry and
biochemistry from the University of Arizona.
“Ron brings a unique blend of scientific expertise, business
acumen, and entrepreneurial spirit to our team,” added Dr.
Donaldson. “His experience leading cross-functional teams and
driving successful product development and commercialization will
help us accelerate our growth and solidify our position as a leader
in the industry.”
These additions come at a critical time for SOLVD Health. In
December, the U.S. Food and Drug Administration approved the
company's AvertD test, making it the first genetic test authorized
to assess the risk of opioid use disorder (OUD) prior to initiating
opioid therapy for acute pain management. AvertD empowers
physicians and patients to make more informed decisions about pain
management options, supporting SOLVD Health's mission to address
pressing healthcare challenges through innovative solutions.
About SOLVD Health SOLVD Health is a privately held
company focused on preventing disease by making contextual health
information accessible to everyone. Through the development of
insights-based health tools, we are enabling individuals and their
providers to make better decisions about their health and the
health of their families. We accomplish this by translating complex
biological signals into actionable patient data that can point the
way to better health. To learn more about us, our solutions, and
our career opportunities, visit us at www.solvdhealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240812577275/en/
Media: Valerie Melucci Vice President of Marketing, SOLVD
Health pr@solvdhealth.com
Investors: Mark Hazeltine Chief Financial Officer, SOLVD
Health investors@solvdhealth.com